Dysregulated Autophagy/Phagocytosis Activates the Immune System in Age-Related Macular Degeneration

Debasish Sinha, PhD
University of Pittsburgh (Pittsburgh, PA)
Year Awarded:
2014
Grant Duration:
July 1, 2014 to June 30, 2016
Disease:
Macular Degeneration
Award Amount:
$120,000
Grant Reference ID:
M2014109
Award Type:
Standard
Award Region:
US Northeastern

This grant is made possible by a gift made in memory of Carolyn K. McGillvray. Recipient of The Carolyn K. McGillvray Award.

Debasish Sinha, PhD

Understanding How Dysregulation of Autophagy/Phagocytosis Activates the Immune System in Retinal Pigmented Epithelium Cells, Leading to Age-Related Macular Degeneration

Summary

The goal of our study is to identify novel targets for the treatment or prevention of age-related macular degeneration (AMD) by better understanding how impaired autophagy and phagocytosis in the retinal pigmented epithelium (RPE) activates the immune system. The RPE is a single layer of pigmented cells situated between the neurosensory retina and the choroid, the vascular layer at the back of the eye. The RPE is involved in the phagocytosis (a cellular function of engulfing and eliminating unnecessary particles) of photoreceptor outer segments (OS). This RPE role is essential for the maintenance and survival of the photoreceptors, or light-sensitive cells. In addition, the RPE is engaged in another form of cellular housekeeping known as autophagy (self-digestion by a cell), and that may be of particular importance because of the very high metabolic activity of RPE. We have generated a new mouse model (an RPE-specific Cryba1 gene knockout mouse) which will serve as a genetic tool to better understand the processes of phagocytosis and autophagy in RPE. Our studies may lead to identification of therapeutic targets for some manifestations of AMD that result from defective phagocytosis and/or autophagy in RPE.

Details

Age-related macular degeneration (AMD) is a complex and progressive degenerative eye disease involving multiple genetic and environmental factors that causes severe loss of central vision. New evidence indicates that dysregulation of the immune system could contribute to the development of AMD. Thus, we will use our RPE-specific Cryba1 gene knockout mouse model to gain a better understanding how impaired autophagy and phagocytosis activate the immune system in retinal pigmented epithelial (RPE) cells, for the ultimate purpose of identifying novel targets for treatment or prevention. We believe that understanding how the immune system is activated and regulated in early AMD will provide us with leads for developing treatments that can be applied at this critical stage of the disease before severe (and probably irreversible) vision loss has occurred.

For Specific Aim 1, we will determine how the loss of ßA3/A1-crystallin from RPE cells affects specifically the terminal stage of autophagy and phagocytosis. In Specific Aim 2, we will determine if chronic impairment of cellular clearance may be the driving force for subsequent immune cell infiltration, leading to an inflammatory response and promoting retinal degeneration. We speculate that dysregulation of lysosomal function can activate excessive retinal inflammation by switching the delicate balance between para-inflammation and inflammatory immune responses, thereby triggering AMD-like pathology. Impaired lysosomal-mediated clearance by autophagy and phagocytosis within the RPE will lead to the accumulation of lysosomal lipofuscin within the cells, as well as formation of extracellular deposits called drusen, two hallmark changes that develop during early AMD. There is no known treatment for early AMD at the present time. Although there is no perfect model for AMD--and while mouse eyes lack a macula--a rodent model that reproduces specific aspects of early AMD would help in the development of prevention and treatment modalities to combat this disease before there is dramatic vision loss. However, even though the mouse has been the model organism most used to study AMD, no mouse model of AMD based on defective endolysosomal function in RPE has been identified.

The goal is to identify novel targets for treatment or prevention of AMD. Our proposed study and disease model will provide a better understanding of the early AMD disease process. We believe that understanding how the immune system is activated and regulated in early AMD will provide us with leads for developing novel treatments that can be applied at this critical stage of the disease before severe (and probably irreversible) vision loss has occurred.

About the Researcher

Debasish Sinha received his PhD degree in immunology followed by a postdoctoral fellowship in molecular biology and genetics at the National Eye Institute. He is an associate professor in the Department of Ophthalmology, at the Johns Hopkins University School of Medicine, with a joint appointment in the Department of Environmental Health Sciences, Bloomberg School of Public Health. He is also a guest professor at The Tongji University School of Medicine, Shanghai, China. His laboratory uses rat spontaneous mutants and genetically engineered mice as genetic tools to explore the functions of glial cells during normal neuronal and vascular development and to probe how abnormalities in glial cells lead to central nervous system diseases. In addition, his laboratory is interested in understanding the processes of autophagy and phagocytosis in retinal pigmented epithelial cells and regulation of the immune system in AMD. His research is funded by the National Institutes of Health, Research to Prevent Blindness and private foundations. He received the Sybil B. Harrington Special Scholar award for Macular Degeneration from the Research to Prevent Blindness as well as The Carolyn K. McGillvray Memorial Award for Macular Degeneration Research from The BrightFocus Foundation. He has been an invited member of the Arnold and Mabel Beckman Conference on Atrophic Macular Degeneration since 2012.

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.